Literature DB >> 22446689

Transcriptional regulators in hepatocarcinogenesis--key integrators of malignant transformation.

Mona Malz1, Federico Pinna, Peter Schirmacher, Kai Breuhahn.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent human malignancies with poor prognosis and increasing incidence in the Western world. Only for a minority of HCC patients, surgical treatment options offer potential cure and therapeutic success of pharmacological approaches is limited. Highly specific approaches (e.g., kinase inhibitors) did not significantly improve the situation so far, possibly due to functional compensation, genetic heterogeneity of HCC, and development of resistance under selective pressure. In contrast, transcriptional regulators (especially transcription factors and co-factors) may integrate and process input signals of different (oncogenic) pathways and therefore represent cellular bottlenecks that regulate tumor cell biology. In this review, we want to summarize the current knowledge about central transcriptional regulators in human hepatocarcinogenesis and their potential as therapeutic target structures. Genomic and transcriptomic data of primary human HCC revealed that many of these factors showed up in subgroups of HCCs with a more aggressive phenotype, suggesting that aberrant activity of transcriptional regulators collect input information to promote tumor initiation and progression. Therefore, expression and dysfunction of transcription factors and co-factors may gain relevance for diagnostics and therapy of HCC.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22446689     DOI: 10.1016/j.jhep.2011.11.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.

Authors:  Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

2.  The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice.

Authors:  C Trierweiler; B Hockenjos; K Zatloukal; R Thimme; H E Blum; E F Wagner; P Hasselblatt
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

3.  Cytotoxic Effect of Bromelain on HepG2 Hepatocellular Carcinoma Cell Line.

Authors:  Sushma S Murthy; T Bala Narsaiah
Journal:  Appl Biochem Biotechnol       Date:  2021-03-18       Impact factor: 2.926

4.  HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.

Authors:  Wei-Min Wang; Yang Xu; Yao-Hui Wang; Hai-Xiang Sun; Yun-Fan Sun; Yi-Feng He; Qing-Feng Zhu; Bo Hu; Xin Zhang; Jing-Lin Xia; Shuang-Jian Qiu; Jian Zhou; Xin-Rong Yang; Jia Fan
Journal:  Oncotarget       Date:  2017-07-18

5.  In silico identification of EP400 and TIA1 as critical transcription factors involved in human hepatocellular carcinoma relapse.

Authors:  Weiguo Hong; Yan Hu; Zhenping Fan; Rong Gao; Ruichuang Yang; Jingfeng Bi; Jun Hou
Journal:  Oncol Lett       Date:  2019-12-02       Impact factor: 2.967

6.  BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.

Authors:  Stephanie Busche; Katharina John; Franziska Wandrer; Florian W R Vondran; Ulrich Lehmann; Heiner Wedemeyer; Frank Essmann; Klaus Schulze-Osthoff; Heike Bantel
Journal:  Cell Death Dis       Date:  2021-07-26       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.